A randomized prospective clinical evaluation of two desensitizing agents on cervical dentine sensitivity. A pilot...

The aim of this prospective clinical pilot study was to evaluate the pain alleviation effectiveness of two desensitizing agents (VivaSens and Seal&Protect) on 30 patients suffering from cervical dentine sensitivity (CDS) over a six month period. Analysis of possible differences in pain alleviation effect between the agents and over time was performed. Further,the experienced pain was registered in a questionnaire regarding to what extent the treatment improved oral health/life quality among the patients. The patients (23 female, 7 male) were randomly divided into two groups. Each group was treated with one of the two desensitizing agents. Sensitivity measurements were recorded before treatment (baseline) and after treatment at time points of one week and six months. The patients were asked to rate the sensitivity experienced in the area during air stimulation by marking on a Visual Analogue Scale (VAS). At six months, 27 patients (90%) had completed the clinical trial. The results showed that a significant reduction of CDS was achieved by using VivaSens or Seal&Protect after both one week and six months. However, there were no differences found on treatment effects between the two desensitizing agents. The results from the questionnaire showed that the patients experienced improved oral health/life quality when comparing the status before and after treatment (0.000 < or = p < or = 0.0021) and there were no statistically significant difference in treatment effects between the products. In conclusion, both desensitizing agents were effective in relieving cervical dentin hypersensitivity during the time course of the study as evaluated both by air stimulation and a questionnaire related to oral health/quality of life status.